Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Ahmad S. Halwani"'
Autor:
Ahmad S. Halwani, Kelli M. Rasmussen, Vikas Patil, Deborah Morreall, Catherine Li, Christina Yong, Zachary Burningham, Keith Dawson, Anthony Masaquel, Kevin Henderson, Elisha DeLong‐Sieg, Brian C. Sauer
Publikováno v:
Cancer Medicine, Vol 9, Iss 20, Pp 7537-7547 (2020)
Abstract Real‐world practice patterns and clinical outcomes in patients with follicular lymphoma (FL), including the adoption of maintenance rituximab (MR) therapy in the United States (US), have been reported in few studies since the release of th
Externí odkaz:
https://doaj.org/article/8499b8c9b6b045c18a609fd2d80fd1a5
Publikováno v:
Leukemia & Lymphoma. 63:2428-2435
Mycosis Fungoides (MF) is a rare T-cell lymphoma and evidence on treatment practices, and outcomes are limited. We evaluated changes in practice patterns and corresponding effects on overall survival (OS) in MF using a cross-sectional study of patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb7332bb9a724f9b005a25a77ed8b583
https://doi.org/10.1080/10428194.2022.2081322
https://doi.org/10.1080/10428194.2022.2081322
Autor:
Ahmad S. Halwani, Carlos Panizo, Iris Isufi, Alex F. Herrera, Craig Y. Okada, Elizabeth H. Cull, Bela Kis, Jorge M. Chaves, Nancy L. Bartlett, Weiyun Ai, Luis de la Cruz-Merino, Locke J. Bryan, Roch Houot, Kim Linton, Javier Briones, Ian Chau, Gottfried R. von Keudell, Hailing Lu, Adam Yakovich, Michael Chen, ter Meulen JH, Sergey Yurasov, Frank J. Hsu, Christopher R. Flowers
Publikováno v:
Leukemia & lymphoma
Leukemia & lymphoma, Taylor & Francis, 2021, ⟨10.1080/10428194.2021.2010057⟩
Leukemia & lymphoma, 2022, 63 (4), pp.821-833. ⟨10.1080/10428194.2021.2010057⟩
LEUKEMIA & LYMPHOMA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Leukemia & lymphoma, Taylor & Francis, 2021, ⟨10.1080/10428194.2021.2010057⟩
Leukemia & lymphoma, 2022, 63 (4), pp.821-833. ⟨10.1080/10428194.2021.2010057⟩
LEUKEMIA & LYMPHOMA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
International audience; Intratumoral injection of G100, a toll-like receptor 4 (TLR4) agonist, was shown pre-clinically to stimulate anti-tumor immune responses and tumor regression. This open-label, multicenter, phase 1/2 trial evaluated the safety,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e37e995b7a7e4fb4d45140e66a7303a
https://doi.org/10.1080/10428194.2021.2010057
https://doi.org/10.1080/10428194.2021.2010057
Autor:
Zachary Burningham, Regina Richter Lagha, Brittany Duford-Hutchinson, Carol Callaway-Lane, Brian C. Sauer, Ahmad S. Halwani, Jamie Bell, Tina Huynh, Joseph R. Douglas, B. Josea Kramer
Publikováno v:
Applied clinical informatics. 13(4)
Background Involving clinician end users in the development process of clinical dashboards is important to ensure that user needs are adequately met prior to releasing the dashboard for use. The challenge with following this approach is that clinicia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fffebfb5a7a71255eefa1702fa3ee1f
https://pubmed.ncbi.nlm.nih.gov/36223868
https://pubmed.ncbi.nlm.nih.gov/36223868
Publikováno v:
JCO clinical cancer informatics. 6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4e4d02dc404e28281389c8c6994087f
https://pubmed.ncbi.nlm.nih.gov/35878071
https://pubmed.ncbi.nlm.nih.gov/35878071
Autor:
Daphne R. Friedman, Vikas Patil, Chunyang Li, Kelli M. Rassmussen, Zachary Burningham, Susan Hamilton-Hill, Michael J. Kelley, Ahmad S. Halwani
Publikováno v:
JCO Clinical Cancer Informatics.
PURPOSE There are growing efforts to integrate patient-reported outcome (PRO) data into electronic health records (EHRs) to bring together disparate sources of patient information and improve medical care. PRO measures can be used to assess cancer sy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e775929a542c4f03088176288c86c255
https://doi.org/10.1200/cci.21.00086
https://doi.org/10.1200/cci.21.00086
Publikováno v:
JCO clinical cancer informatics. 6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4d9bdcc921aa286d4223203649edc37
https://pubmed.ncbi.nlm.nih.gov/35353547
https://pubmed.ncbi.nlm.nih.gov/35353547
Autor:
Kelli M, Rasmussen, Vikas, Patil, Zachary, Burningham, Christina, Yong, Brian C, Sauer, Ahmad S, Halwani
Publikováno v:
Fed Pract
BACKGROUND: Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults. The introduction of novel oral agents, starting with ibrutinib in 2013, has revolutionized the therapeutic landscape; however, clinical trials have suggeste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::84eb3a6014ee87629e52a0012b05ecde
https://pubmed.ncbi.nlm.nih.gov/32952387
https://pubmed.ncbi.nlm.nih.gov/32952387
Autor:
Ahmad S. Halwani, Catherine Li, Kelli M. Rasmussen, Vikas Patil, Christina Yong, Zachary Burningham, Brian C. Sauer
Publikováno v:
Cancer Research. 79:3309-3309
OBJECTIVES: Examine healthcare resource utilization (HCRU) in follicular lymphoma (FL) patients treated with or without maintenance rituximab (MR). METHODS: FL patients treated in the Veterans Health Administration (VHA) between 2006-2014 were identi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfe4dbc93cf9d3f926ed5a5cd0f66609
https://doi.org/10.1158/1538-7445.am2019-3309
https://doi.org/10.1158/1538-7445.am2019-3309
Autor:
Youn H. Kim, Martine Bagot, Pier Luigi Zinzani, Madeleine Duvic, Stephen Morris, Ellen Kim, Amy Musiek, Pablo L. Ortiz-Romero, Craig Elmets, Herbert A. Eradat, Nina Magnolo, Julia Scarisbrick, Stéphane Dalle, David C. Fisher, Michi Shinohara, Brian Poligone, Barbara Pro, Pietro Quaglino, Nishitha Reddy, Brigitte Dreno, Larisa J Geskin, Ahmad S Halwani, Amit Khot, Marie Beylot-Barry, Neil Korman, Frederick Lansigan, Steven M. Horwitz, Zanetta S. Lamar, Alison J. Moskowitz, Jillian Wells, Oleg E. Akilov, Dolores Caballero, Richard Cowan, Reinhard Dummer, Mary Jo Lechowicz, Francine M. Foss, Lars Iversen, Tomomitsu Miyagaki, Ryan Wilcox, Pierluigi Porcu, Maarten Vermeer, Sunil Abhyankar, Yukihiko Kato, Theresa Pacheco, Shigetoshi Sano, Basem M. William, Timothy S. Fenske, Noriko Fukuhara, Koji Habe, Toshihisa Hamada, Eiji Kiyohara, Bryone J. Kuss, Adam Lerner, Lawrence Mark, Javier Munoz, Hiroyuki Okamoto, Christiane Querfeld, Jiro Uehara, Hisashi Uhara, Kentaro Yonekura, Auris Huen, Kensei Tobinai, Yoshiki Tokura, Erin Boh, Jan Nicolay, Hidefumi Wada, Mollie Leoni, Takahiro Ito, Fiona Herr, Lubomir Sokol
Publikováno v:
Blood. 134:5300-5300
Introduction: MAVORIC was an open-label, multicenter, randomized phase 3 study evaluating the safety and efficacy of mogamulizumab (moga) compared to vorinostat (vori) in patients with mycosis fungoides (MF) or Sézary syndrome (SS) who had failed at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c51d9bc27e6a104d6dc1b97fec00a23e
https://doi.org/10.1182/blood-2019-122778
https://doi.org/10.1182/blood-2019-122778